2.1 Pure Food and Drug Act through FDCA, Durham-Humphrey & Kefauver-Harris

2.1 Pure Food and Drug Act through FDCA, Durham-Humphrey & Kefauver-Harris

Federal statutory drug law serves as the baseline regulatory foundation for all pharmacy practice across the United States. In the Commonwealth of Tennessee, as in all jurisdictions, pharmacy candidates must master federal drug statutes because state pharmacy law builds upon, incorporates, and frequently tightens these federal mandates. Under the constitutional doctrine of concurrent state and federal jurisdiction, federal law sets the absolute regulatory floor beneath which no state may fall.

---

1. Historical Evolution of Federal Drug Regulation

Understanding the historical catalysts behind major federal drug enactments is essential for the MPJE, as exam items frequently test the specific statutory remedy created in response to historical public health tragedies.

Pure Food and Drug Act of 1906 (The Wiley Act)

• Legislative Catalyst: Public outrage generated by muckraking journalism (including Upton Sinclair's The Jungle) and Dr. Harvey Wiley's "Poison Squad" investigations exposed widespread contamination, toxic preservatives, and fraudulent "patent medicines" containing undisclosed narcotics and alcohol.
• Statutory Mandates: Prohibited the introduction into interstate commerce of adulterated or misbranded foods and drugs. Required that labels accurately state the quantity or proportion of certain specified dangerous substances (such as alcohol, morphine, opium, cocaine, and cannabis).
• Statutory Shortcomings: The 1906 Act did not require pre-market approval, did not require proof of safety or efficacy, did not grant the federal government authority to inspect manufacturing facilities, and did not apply to cosmetics or medical devices. Furthermore, in United States v. Johnson (1911), the U.S. Supreme Court ruled that the misbranding provisions of the 1906 Act prohibited only false statements regarding the identity or composition of the drug, not false therapeutic or efficacy claims.
• The Sherley Amendment of 1912: Congress amended the 1906 Act to prohibit false and fraudulent therapeutic claims. However, it placed an enormous enforcement burden on the government, requiring prosecutors to prove subjective intent to defraud on the part of the manufacturer.

The Sulfanilamide Disaster & The Food, Drug, and Cosmetic Act of 1938

• Legislative Catalyst: In 1937, S.E. Massengill Co. manufactured an oral liquid formulation of sulfanilamide (the first modern antimicrobial) formulated with diethylene glycol (antifreeze) as a solvent to create "Elixir Sulfanilamide." Over 100 people, mostly pediatric patients, died from acute renal failure. Under the 1906 Act, the FDA could only seize the product on a technicality: an "elixir" was statutorily defined as an alcoholic solution, whereas Massengill's preparation contained no alcohol (misbranding).
• The FDCA of 1938 (21 U.S.C. § 301 et seq.): Congress overhauled federal drug law with landmark legislation that remains the core statutory architecture today:
  1. Pre-Market Proof of Safety: For the first time, manufacturers were required to submit a New Drug Application (NDA) establishing that a drug was safe for human use under the conditions prescribed on its label prior to commercial distribution.
  2. Adequate Directions for Use & Warnings: Required labels to carry "adequate directions for use" and warnings against habit-forming substances.
  3. Expanded Scope: Extended FDA regulatory jurisdiction to include cosmetics and therapeutic medical devices.
  4. Factory Inspections: Authorized federal factory inspections to enforce sanitary standards.
  5. Codified Adulteration and Misbranding: Established the modern statutory definitions and criminal penalties for adulteration (21 U.S.C. § 351) and misbranding (21 U.S.C. § 352).

Durham-Humphrey Amendment of 1951 (Prescription Drug Amendment)

Prior to 1951, the 1938 FDCA placed the burden on manufacturers to determine whether a drug required a prescription, resulting in chaos where identical chemical entities were sold OTC by one manufacturer and as prescription-only by another.

• Statutory Creation of Two Drug Classes: The 1951 Amendment established the legal division between prescription (legend) drugs and non-prescription (over-the-counter or OTC) drugs.
• Statutory Criteria for Prescription Classification: A drug must be dispensed by prescription only if:
  1. It is habit-forming;
  2. Due to its toxicity or other potentiality for harmful effect, the method of its use, or the collateral measures necessary to its use, it is not safe for use except under the supervision of a practitioner licensed by law to administer such drug; or
  3. It is limited to prescription dispensing under an approved New Drug Application (NDA).
• Statutory Legend: Mandated that prescription drug containers bear the manufacturer warning: "Caution: Federal law prohibits dispensing without prescription" (shortened by FDAMA 1997 to "Rx Only").
• Legalization of Verbal Prescriptions & Refills: Explicitly authorized licensed pharmacists to dispense oral (telephoned/verbal) prescriptions and to fulfill verbal or written refill authorizations from prescribers.

Kefauver-Harris Drug Amendments of 1962 (Drug Efficacy Amendment)

• Legislative Catalyst: In the late 1950s and early 1960s, thalidomide was widely prescribed in Europe as a sedative and anti-nausea medication for morning sickness in pregnancy. It caused thousands of infants to be born with severe phocomelia (seal-like limb-reduction malformations). Dr. Frances Kelsey, an FDA medical officer, withheld U.S. approval because of safety concerns, largely sparing the American public.
• Statutory Mandates of 1962:
  1. Proof of Substantial Efficacy: Required manufacturers to prove through adequate, well-controlled clinical trials that a drug is not only safe, but substantially effective for all claimed therapeutic indications prior to marketing.
  2. Retroactive Review (DESI): Applied efficacy standards retroactively to all drugs approved between 1938 and 1962 under the Drug Efficacy Study Implementation (DESI) program.
  3. Current Good Manufacturing Practices (cGMP): Established statutory requirements for cGMP (21 CFR Parts 210 and 211), making any drug manufactured in non-compliant facilities statutorily adulterated.
  4. Advertising Jurisdiction: Transferred prescription drug advertising oversight from the Federal Trade Commission (FTC) to the FDA (the FTC retains regulatory authority over OTC drug advertising).
  5. Clinical Research Safeguards: Mandated informed consent from research subjects in clinical investigations and instituted mandatory post-marketing adverse drug reaction reporting.

Subsequent Landmark Federal Amendments

• Medical Device Amendments of 1976: Classified medical devices into Class I (general controls), Class II (performance standards), and Class III (pre-market approval for life-sustaining/implantable devices).
• Orphan Drug Act of 1983: Provided tax incentives, research grants, and 7 years of market exclusivity for manufacturers developing therapies for rare diseases affecting fewer than 200,000 individuals in the U.S.
• Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act): Created the modern generic drug approval pathway via the Abbreviated New Drug Application (ANDA under 21 U.S.C. § 355(j)). Generics must prove bioequivalence (80%–125% confidence interval for Cmax and AUC) without repeating clinical safety and efficacy trials. Granted brand manufacturers up to 5 years of patent term restoration.
• Prescription Drug Marketing Act (PDMA) of 1987: Prohibited re-importation of American-made prescription drugs except by the original manufacturer; banned the sale, purchase, or trade of prescription drug samples; prohibited retail pharmacies from possessing prescription drug samples under any circumstances; and required drug wholesalers to hold state licensure.
• Dietary Supplement Health and Education Act (DSHEA) of 1994: Classified dietary supplements as foods rather than drugs. Prohibited the FDA from requiring pre-market safety or efficacy testing. Permitted manufacturers to make structure/function claims provided the label carries the mandatory disclaimer ("This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease").
• Food and Drug Administration Modernization Act (FDAMA) of 1997: Streamlined FDA approval processes; shortened the prescription legend to "Rx Only"; permitted manufacturers to disseminate peer-reviewed journal articles regarding off-label uses; and provided a 6-month pediatric exclusivity incentive.
• Food and Drug Administration Amendments Act (FDAAA) of 2007: Granted the FDA statutory authority to mandate Risk Evaluation and Mitigation Strategies (REMS) and require post-marketing clinical trials (Phase IV).
• Drug Quality and Security Act (DQSA) of 2013: Enacted following the 2012 New England Compounding Center (NECC) fungal meningitis outbreak. Divided compounding into Section 503A (traditional, patient-specific state-regulated pharmacies) and Section 503B (voluntary outsourcing facilities subject to cGMP and FDA inspection). Title II established the Drug Supply Chain Security Act (DSCSA), creating a 10-year phased track-and-trace framework using product identifiers and the "3 Ts" (Transaction Information, Transaction History, and Transaction Statement).

---

2. Adulteration vs. Misbranding: The Core Legal Framework

Adulteration and misbranding are the twin pillars of federal drug enforcement. On the MPJE, questions frequently test whether a specific clinical, manufacturing, packaging, or dispensing irregularity constitutes adulteration, misbranding, both, or neither.

Adulteration (21 U.S.C. § 351)

Adulteration pertains primarily to the physical composition, cleanliness, strength, quality, purity, or manufacturing conditions of the drug product. Under the statute, a drug or device is deemed adulterated if:

1. Insanitary Conditions: It has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. Critical Exam Principle: The drug does not need to be contaminated in fact; exposure to conditions where contamination could occur satisfies statutory adulteration.
2. cGMP Violations: It is manufactured, processed, packed, or held in violation of Current Good Manufacturing Practice regulations (21 CFR Parts 210/211). Even if a finished tablet tests 100% chemically pure, failure to adhere to cGMP makes it legally adulterated.
3. Deleterious Container: Its container is composed, in whole or in part, of any poisonous or deleterious substance which may render the contents injurious to health.
4. Unsafe Additives: It bears or contains an unsafe color additive or unapproved preservative.
5. Strength Differs from Compendial Standard: It purports to be or is represented as a drug recognized in an official compendium (United States Pharmacopeia / National Formulary, USP-NF), and its strength differs from, or its quality or purity falls below, the standard set forth in such compendium, unless such difference is plainly stated on its label.
6. Strength Differs from Labeled Strength: It is not recognized in an official compendium, but its strength differs from, or its purity or quality falls below, that which it purports or is represented to possess on its label.
7. Substituted Substance: Any substance has been mixed or packed with it so as to reduce its quality or strength, or substituted wholly or in part therefor.
8. Improper Storage / Expired Stock: An expired drug in active pharmacy dispensing stock, or a drug exposed to extreme temperature/humidity excursions outside USP storage parameters (e.g., reconstituted amoxicillin left at room temperature), is legally adulterated because its potency and stability cannot be guaranteed.

Misbranding (21 U.S.C. § 352)

Misbranding pertains primarily to the label, written representations, packaging, omitted statutory warnings, advertising, and the legality of the dispensing act itself. Under the statute, a drug or device is deemed misbranded if:

1. False or Misleading Labeling: Its labeling is false or misleading in any particular.
2. Missing Manufacturer Information: The commercial container fails to bear a label containing the name and place of business of the manufacturer, packer, or distributor, and an accurate statement of the quantity of the contents in terms of weight, measure, or numerical count.
3. Omitted Active or Inactive Ingredients: The label fails to state the established (generic) name of the drug, the established name and quantity of each active ingredient, and (for prescription drugs) the established name of each inactive ingredient.
4. Lack of Adequate Directions for Use: The product lacks adequate directions for use (a statutory mandate for OTC products, enabling a layperson to self-medicate safely) or lacks adequate information for use (the package insert/professional labeling required for prescription drugs).
5. Omitted Warnings: It lacks adequate warnings against use in pathological conditions or by children where its use may be dangerous to health.
6. Imitation Drugs & Counterfeits: It is an imitation of another drug, or is offered for sale under the name of another drug.
7. Omission of Required Legend: The commercial container of a prescription drug fails to bear the symbol "Rx Only".
8. Violations of the Poison Prevention Packaging Act (PPPA): A prescription dispensed in non-child-resistant packaging without an authorized patient or prescriber waiver is statutorily misbranded.
9. Dispensing Without a Valid Prescription or Refill: Under FDCA Section 503(b)(1) (21 U.S.C. § 353(b)(1)), the act of dispensing a prescription legend drug without a valid prescription, or refilling a prescription without authorization from the prescriber, is deemed an act of statutory misbranding.
10. Prescription Label Deficiencies: An outpatient prescription label that omits required statutory elements (e.g., patient name, pharmacy name/address, directions, prescriber name, prescription number) renders the dispensed medication misbranded.

Comprehensive Comparison: Adulteration vs. Misbranding

---

3. FDA Drug Approval Pathways

To be commercially distributed in interstate commerce, a new drug must navigate statutory FDA approval pathways codified in Section 505 of the FDCA (21 U.S.C. § 355).

┌─────────────────────────────────────────────────────────────────────────────┐
│                     FDA DRUG APPROVAL PATHWAY OVERVIEW                      │
├──────────────────────────────────┬──────────────────────────────────────────┤
│ Pathway & Statutory Basis        │ Clinical & Regulatory Requirements       │
├──────────────────────────────────┼──────────────────────────────────────────┤
│ Investigational New Drug (IND)   │ Pre-clinical animal toxicity completed;  │
│ (21 CFR Part 312)                │ authorizes human clinical testing.       │
├──────────────────────────────────┼──────────────────────────────────────────┤
│ New Drug Application (NDA)       │ Full reports of safety & efficacy;       │
│ Section 505(b)(1)                │ Phase I, II, and III clinical trials.    │
├──────────────────────────────────┼──────────────────────────────────────────┤
│ Section 505(b)(2) Application    │ Relies partly on FDA findings for an     │
│                                  │ existing drug (new indication/form).     │
├──────────────────────────────────┼──────────────────────────────────────────┤
│ Abbreviated New Drug App (ANDA)  │ Proves bioequivalence & pharmaceutical   │
│ Section 505(j) (Hatch-Waxman)    │ equivalence; no animal/clinical trials.  │
├──────────────────────────────────┼──────────────────────────────────────────┤
│ Supplemental NDA (sNDA)          │ Post-approval changes: new indications,  │
│ (21 CFR § 314.70)                │ dosage forms, or manufacturing methods.  │
└──────────────────────────────────┴──────────────────────────────────────────┘

Clinical Investigation Phases (Under an Active IND)

• Phase I: Evaluates drug safety, pharmacokinetics, pharmacodynamics, and safe dosage range in a small group of healthy human volunteers (typically 20 to 80 subjects).
• Phase II: Evaluates efficacy, optimal dosing regimens, and short-term adverse effects in a targeted population of subjects with the disease or condition (typically 100 to 300 patients).
• Phase III: Confirms efficacy, monitors adverse reactions from long-term exposure, and compares the drug to standard-of-care placebos or active controls in large, randomized, controlled multi-center clinical trials (typically 1,000 to 3,000+ patients).
• Phase IV (Post-Marketing Surveillance): Clinical studies conducted after commercial approval to monitor long-term safety, real-world adverse outcomes, and efficacy across diverse populations.

Generic Drug Approval & The FDA Orange Book

Under the Hatch-Waxman Act of 1984, generic manufacturers submit an ANDA under FDCA Section 505(j). The generic sponsor must establish two statutory requirements:

1. Pharmaceutical Equivalence: Identical active ingredient(s), identical dosage form, identical strength, and identical route of administration, meeting identical compendial standards of purity and quality (inactive excipients may differ).
2. Bioequivalence: Demonstrates that the rate and extent of absorption of the generic active ingredient does not show a significant difference from the reference listed drug (RLD) when administered at the same molar dose (standard statistical metric: 90% confidence intervals for Cmax and AUC must fall between 80.00% and 125.00%).

The FDA publishes approved generic equivalence ratings in the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations):

• "A" Rated Products: Considered therapeutically equivalent to the reference drug and therapeutically substitutable.
  • AB Rating: Products meeting necessary bioequivalence requirements through in vivo and/or in vitro testing.
  • AA, AN, AO, AP, AT: Therapeutically equivalent formulations in specific dosage forms (e.g., AP = injectable aqueous solutions; AT = topical products).
• "B" Rated Products: Products that the FDA currently considers not therapeutically equivalent due to actual or potential bioequivalence problems that have not been resolved (cannot be substituted without prescriber consent).

---

4. Risk Evaluation and Mitigation Strategies (REMS)

Established under the Food and Drug Administration Amendments Act (FDAAA) of 2007 (codified in FDCA Section 505-1), the FDA has authority to require a manufacturer to submit a REMS if the FDA determines that safety measures beyond approved labeling are necessary to ensure that the drug's benefits outweigh its risks.

The Four REMS Elements

1. Medication Guide or Patient Package Insert (PPI): Mandatory patient educational materials distributed at dispensing.
2. Communication Plan: Targeted scientific safety materials sent to healthcare providers, professional societies, and licensing boards.
3. Elements to Assure Safe Use (ETASU): The most stringent REMS interventions, which may require that:
   • Healthcare providers who prescribe the drug have particular training or certification;
   • Pharmacies and healthcare settings that dispense the drug are specially certified;
   • The drug is dispensed only to patients with evidence of safe-use conditions (e.g., negative pregnancy tests, laboratory monitoring);
   • Each patient is enrolled in a specialized surveillance registry.
4. Implementation System: A comprehensive tracking and auditing mechanism maintained by the manufacturer to monitor pharmacy and provider compliance.

Landmark Clinical REMS Programs

• Clozapine REMS: Manages the risk of severe, life-threatening neutropenia and agranulocytosis. Prescribers and pharmacies must be certified. Before dispensing, the pharmacy must obtain a Pre-Dispense Authorization (PDA) confirming that the patient's absolute neutrophil count (ANC) is within safe limits (ANC $\ge 1,500/\mu\text{L}$ for the general population; $\ge 1,000/\mu\text{L}$ for patients with documented Benign Ethnic Neutropenia [BEN]).
• Isotretinoin (iPLEDGE REMS): Manages the risk of severe teratogenicity, microcephaly, and spontaneous abortion. Requires prescribers, pharmacies, and patients (male and female) to register. Females of childbearing potential must have two consecutive negative urine/blood pregnancy tests prior to initiating therapy and monthly negative tests thereafter. Prescriptions have strict validity windows: 7 days from the pregnancy test date for females of reproductive potential, and 30 days from the office visit for non-reproductive females and males. Maximum 30-day supply; zero refills permitted.
• Transmucosal Immediate-Release Fentanyl (TIRF REMS): Restricts use strictly to breakthrough cancer pain in opioid-tolerant adult patients (defined as taking at least 60 mg oral morphine daily, 30 mg oral oxycodone daily, 8 mg oral hydromorphone daily, or equianalgesic doses for $\ge 1$ week). Outpatient pharmacies and prescribers must be certified.
• Thalidomide (Thalomid REMS): Restricts dispensing to prevent devastating phocomelia birth defects. Requires mandatory registry enrollment, verified contraception, and a 28-day supply limit with no refills.

---

5. Post-Marketing Surveillance & FDA MedWatch Reporting

Once a drug reaches the marketplace, adverse events are monitored through Phase IV studies and the FDA MedWatch program.

• Scope of MedWatch: Serves as the FDA's Safety Information and Adverse Event Reporting Program. Collects reports regarding prescription and OTC drugs, biologics, medical devices, special nutritional products, dietary supplements, and cosmetics.
• What to Report: Serious adverse events (death, life-threatening outcomes, hospitalization, disability, congenital anomalies), product quality problems (contamination, stability failures, defective delivery systems), therapeutic failures, and medication errors.
• Vaccines are EXCLUDED: Adverse events involving vaccines must be reported to the VAERS (Vaccine Adverse Event Reporting System) co-managed by the CDC and FDA, not to MedWatch.
• Reporting Mandates: Healthcare professionals (pharmacists, physicians, nurses) and consumers participate in MedWatch on a voluntary basis. However, pharmaceutical manufacturers are subject to mandatory adverse event reporting under federal law.

---

6. FDA Drug Recalls: Classifications & Legal Mechanics

A drug recall is an action taken by a manufacturer to remove or correct a marketed product that violates the laws administered by the FDA. While the FDA has mandatory recall authority for medical devices, biological products, human tissue, infant formulas, and controlled substances (under 21 U.S.C. § 823), for most prescription legend drugs, recalls are technically voluntary actions initiated by the manufacturer, either independently or at the formal request of the FDA. If a manufacturer refuses an FDA recall request, the FDA can enforce compliance through federal court action: obtaining a seizure order (21 U.S.C. § 334) to confiscate the drug, or filing for a federal injunction (21 U.S.C. § 332) to halt production and interstate distribution.

┌─────────────────────────────────────────────────────────────────────────────┐
│                         FDA DRUG RECALL CLASSIFICATIONS                     │
├──────────────┬───────────────────────────────┬──────────────────────────────┤
│ Class        │ Hazard / Health Risk Standard │ Operational & Pharmacy Scope │
├──────────────┼───────────────────────────────┼──────────────────────────────┤
│ Class I      │ Reasonable probability that   │ Urgent action; immediate     │
│ (Highest)    │ exposure will cause serious   │ quarantine; retrieval down   │
│              │ adverse health consequences   │ to the patient / consumer    │
│              │ or death.                     │ level required.              │
├──────────────┼───────────────────────────────┼──────────────────────────────┤
│ Class II     │ Exposure may cause temporary  │ Retrieval down to the        │
│ (Moderate)   │ or medically reversible harm; │ retail pharmacy, hospital,   │
│              │ probability of serious harm   │ and wholesale level;         │
│              │ is remote.                    │ patient contact rare.        │
├──────────────┼───────────────────────────────┼──────────────────────────────┤
│ Class III    │ Exposure is not likely to     │ Retrieval typically confined │
│ (Lowest)     │ cause adverse health          │ to wholesaler / distributor  │
│              │ consequences.                 │ level (minor label error).   │
└──────────────┴───────────────────────────────┴──────────────────────────────┘

Clinical Recall Examples

• Class I Example: A commercial injectable vial labeled as 0.9% Normal Saline is found to be contaminated with Pseudomonas aeruginosa, or a commercial pediatric suspension contains an undeclared, life-threatening allergen, or a critical cardiac tablet has double the labeled potency. The pharmacy must immediately inspect stock, quarantine remaining vials, and actively contact patients who received the recalled lot.
• Class II Example: A batch of antihypertensive tablets is found to have a slight dissolution failure that may cause reduced bioavailability, or a sterile eye drop bottle has an exterior packaging flaw that could compromise long-term sterility over several months. Outpatient pharmacies pull the stock from shelves; patient notification is generally not required unless clinically directed.
• Class III Example: A bottle of multivitamins has a misspelled word in the inactive ingredient list, or the manufacturer's font size on the outer carton violates a technical labeling specification, or the container closure exhibits minor ink smudging. Wholesalers return stock; patient risk is negligible.